in this annually report , unless otherwise specified , all dollar amounts are expressed in united states dollars and all references to “ common shares ” refer to the common shares in our capital stock . as used in this annually report and unless otherwise indicated , the terms “ we ” , “ us ” , “ our ” , `` jupw `` and the “ company ” mean jupiter wellness , inc. company overview we were originally incorporated in the state of delaware on october 24 , 2018. our principal business address is 725 n. hwy a1a , suite c-106 , jupiter , fl 33477. jupiter wellness , inc. is a cutting-edge developer of cannabidiol ( cbd ) based medical therapeutics and wellness products . the company 's clinical pipeline of prescription cbd-enhanced skin care therapeutics address indications including eczema , burns , herpes cold sores , and skin cancer . we are in the early stage of manufacturing , distributing , and marketing a diverse line of consumer products infused with cbd . we have a proprietary , line of products : canisun , caniskin and canidermrx . under the canisun brand , we are marketing patent pending cbd-infused sun care lotion formulas containing various sun protection factors , or spfs . in addition , we are exploring the use of cbd with other prescription and or over-the-counter , or otc , consumer products that have potentially therapeutic and medical applications . specifically , we are exploring the use of such topical solutions for the treatment of eczema , dermatitis ( jw-100 ) , and actinic keratosis ( jw-_100 ) , a non-prescription lotion/lip balm ( jw-200 ) for the treatment of symptoms of cold sores , and a prescription product for the treatment of burns ( jw-101 ) . the canidermrx ( jw-100 ) topical solution for the treatment of eczema dermatitis is the lead product candidate and will be further tested in humans as an investigational cosmetic ingredient followed by clinical trials subject to the regulations of the united states food and drug administration ( “ fda ” ) under an investigational new drug , or ind , application . in february 2021 , we announced the results of our novel cannabidiol-aspartame combination treatment jw-100 clinical trial which has shown it significantly reduces isga score in eczema patients . a double blinded placebo controlled interventional study was conducted . subjects were assigned to apply , at home , one of three treatments : jw-100 ( a cbd and aspartame combination topical formulation ) , a cbd only topical formulation , or a placebo topical formulation . after 14 days , the average reduction in the investigators static global assessment ( isga ) score was calculated for each group . additionally , the proportion of subjects achieving ( isga ) score 0 ( clear ) or 1 ( almost clear ) with at least 2 grade improvement from baseline was recorded for each arm of the study . 50 % of subjects in the jw-100 arm achieved isga clear or almost clear ( 1 or 2 ) with at least a 2-grade improvement from baseline after treatment versus 20 % and 15 % in the cbd-only and placebo arms , respectively . the percentage of subjects achieving clear or almost clear with at least a 2-grade improvement from baseline was found to be statistically significant ( p=0.028 ) . jw-100 , a novel topical formulation containing cbd and aspartame , was shown to significantly reduce isga score in atopic dermatitis patients after two weeks of use . the combination of cbd and aspartame was more effective at reducing isga scores than cbd alone . in parallel , we plan to initiate the development of other products . we originally anticipated developmental studies to be completed in 2020 , however , these studies were delayed due to covid-19 . we are also actively seeking to acquire or license products in the otc skin care market that can be infused with cbd and marketed under our caniskin and canidermrx brand names . there can be no assurances that we will acquire or enter into such partnership or licensing agreements . the endocannabinoid system , which is a body system affected by cbd , plays a pivotal role in maintaining a healthy skin through modulating pain sensation , cell proliferation and inflammation . our strategy for treatment of skin indications is , therefore , to focus on the use of cbd containing topical formulations and to explore potential combinations of cbd and other agents that may augment and act synergistically with cbd . we will explore this strategy by conducting controlled clinical trials to try to ultimately gain fda approval for specific indications . 31 canisun brand we developed a cbd-infused sunscreen with broad-spectrum spf protection . we have completed lab testing for cbd solubility-infusing clear , colorless , odorless , and 99.5 % pure cbd isolated with three different sun care active ingredients , homosalate , octisalate and octocrylene , which have already been approved by the fda . the cbd-infused sun care market is fairly nascent in the united states ; we believe that there are currently no major competitors in the category . we see an opportunity to become the leading manufacturer of cbd-infused sun care products , marketing the canisun brand through an extensive digital and social media awareness campaign . we announced the launch of our canisun sun care line of spf 30 , spf 50 and spf 55 face lotion on june 6 , 2019. we also sell our cbd-infused lip balm and cbd-infused spf 30 sunscreen spray on our website canisun.com . story_separator_special_tag from january through september 2019 , we had multiple sales of common stock at $ 0.25 per share . from september through the end of 2019 , we sold our stock at $ 1.00 per share . issuances and grants throughout 2019 were all based upon the last sales price for sales of our stock for cash to third parties . if and when our shares of common stock are publicly listed , we will use the closing share price on a exchange as a basis for valuing our stock grants . recently issued accounting pronouncements in june 2018 , the fasb issued asu 2018-07 , which simplifies the accounting for nonemployee share-based payment transactions . the amendments specify that topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor 's own operations by issuing share-based payment awards . the company has adopted this standard beginning january 1 , 2019. the adoption of this standard did not have a significant impact on our results of operations , financial condition , cash flows , and financial statement disclosures . in may 2014 , the fasb issued asu no . 2014-09 , “ revenue from contracts with customers ” . the new standard provides a five-step approach to be applied to all contracts with customers and also requires expanded disclosures about revenue recognition . the asu is effective for annual reporting periods beginning after december 15 , 2017 , including interim periods and is to be retrospectively applied . the adoption of this standard did not have a significant impact on our results of operations , financial condition , and cash flows . the adoption of this standard is expected to result in additional financial statement disclosures . in february 2016 , topic 842 , “ leases ” was issued to replace the leases requirements in topic 840 , “ leases ” . the main difference between previous gaap and topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous gaap . a lessee should recognize in the balance sheet a liability to make lease payments ( the lease liability ) and a right-of-use asset representing its right to use the underlying asset for the lease term . for leases with a term of 12 months or less , a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities . if a lessee makes this election , it should recognize lease expense for such leases generally on a straight-line basis over the lease term . the accounting applied by a lessor is largely unchanged from that applied under previous gaap . topic 842 will be effective for annual reporting periods beginning after december 15 , 2018 , including interim periods within those annual periods and is to be retrospectively applied . the company has adopted this standard beginning january 1 , 2019. the adoption of this standard did not have a significant impact on our results of operations , financial condition , cash flows , and financial statement disclosures . management does not believe that any recently issued , but not effective , accounting standards , if currently adopted , would have a material effect on our financial statements . 35 results of operations for the year ended december 31 , 2020 the following table provides selected financial data about us for the year ended december 31 , 2020 and 2019 , respectively . replace_table_token_2_th revenues we generated $ 1,065,665 in revenues for the year ended december 31 , 2020 compared to $ 6,455 revenues for the year ended december 31 , 2019. the large increase is due to the company having only nominal operations during 2019. in 2019 , the company focused its efforts on formulating , testing and manufacturing its sunscreen and skin care products . in 2020 , the company ( i ) began marketing its skin care and sunscreen products line , ( 2 ) acquired magical beasts , llc , which expanded its product offerings , sales and marketing capabilities ( 3 ) added additional product lines to its skin care product line , ( 4 ) added a line of hand sanitizer , for a combined sales total of $ 834,812 and acquired srm entertainment ltd which contributed sales of $ 230,853. operating expenses we had total operating expenses of $ 6,730,300 for the year ended december 31 , 2020 compared to $ 913,893 for the year ended december 31 , 2019. operating expenses for the year ended december 31 , 2020 were in connection with our daily operations as follows : ( i ) marketing expenses of $ 82,367 ; ( ii ) research and development of $ 308,367 ; ( iii ) legal and professional expenses of $ 837,698 , consisting of corporate advisory services , registration statement preparation fees , general corporate governance fees ; ( iv ) rent of $ 61,797 ; ( v ) depreciation and amortization of $ 103,392 ; ( vi ) general and administrative expenses of $ 1,784,456 , consisting of payroll and related taxes , travel , meals and entertainment , office supplies and expense and other normal office and administration expenses ; ( vii ) stock based compensation of $ 2,398,140 ; ( viii ) an impairment to goodwill of $ 308,690 ; ( ix ) an impairment to intangible assets of $ 731,628 and ( x ) net interest expense of $ 113,765. we had total operating expenses of $ 913,893 for the year ended december 31 , 2019. operating expenses were in connection with our daily operations as follows : ( i ) marketing expenses of $ 74,145 consisting of internet awareness costs , website development , trade shows and promotional displays ; ( ii ) research and development of $ 108,957 consisting of product

cash we consider all short-term investments with a maturity of three months or less when purchased to be cash and equivalents for purposes of the statement of cash flows . there were no cash equivalents as december 31 , 2020 and 2019. foreign currency translation assets and liabilities in foreign currencies are translated using the exchange rate at the balance sheet date , while revenue and expense accounts are translated at the average exchange rates prevailing during the period . equity accounts are translated at historical exchange rates . gains and losses from foreign currency transactions and translation for the years ended december 31 , 2020 and 2019 and the cumulative translation gains and losses as of december 31 , 2020 and 2019 were not material . accounts receivable accounts receivable are generated from sales of the company 's products . the company provides an allowance for doubtful collections , which is based upon a review of outstanding receivables , historical collection information , and existing economic conditions . as of december 31 , 2020 the company recorded an allowance of $ 118,761 against accounts receivable acquired in connection with the acquisition of srm entertainment and as of december 31 , 2020 , the company had recognized no allowance for doubtful collections . fair value of financial instruments the fair value of our assets and liabilities , which qualify as financial instruments under asc topic 820 , “ fair value measurements and disclosures , ” approximates the carrying amounts represented in the accompanying balance sheet , primarily due to their short-term nature . 34 income taxes we account for income taxes under asc 740 income taxes ( “ asc 740 ” ) .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash we consider all short-term investments with a maturity of three months or less when purchased to be cash and equivalents for purposes of the statement of cash flows . there were no cash equivalents as december 31 , 2020 and 2019. foreign currency translation assets and liabilities in foreign currencies are translated using the exchange rate at the balance sheet date , while revenue and expense accounts are translated at the average exchange rates prevailing during the period . equity accounts are translated at historical exchange rates . gains and losses from foreign currency transactions and translation for the years ended december 31 , 2020 and 2019 and the cumulative translation gains and losses as of december 31 , 2020 and 2019 were not material . accounts receivable accounts receivable are generated from sales of the company 's products . the company provides an allowance for doubtful collections , which is based upon a review of outstanding receivables , historical collection information , and existing economic conditions . as of december 31 , 2020 the company recorded an allowance of $ 118,761 against accounts receivable acquired in connection with the acquisition of srm entertainment and as of december 31 , 2020 , the company had recognized no allowance for doubtful collections . fair value of financial instruments the fair value of our assets and liabilities , which qualify as financial instruments under asc topic 820 , “ fair value measurements and disclosures , ” approximates the carrying amounts represented in the accompanying balance sheet , primarily due to their short-term nature . 34 income taxes we account for income taxes under asc 740 income taxes ( “ asc 740 ” ) .
```    
 Suspicious Activity Report : in this annually report , unless otherwise specified , all dollar amounts are expressed in united states dollars and all references to “ common shares ” refer to the common shares in our capital stock . as used in this annually report and unless otherwise indicated , the terms “ we ” , “ us ” , “ our ” , `` jupw `` and the “ company ” mean jupiter wellness , inc. company overview we were originally incorporated in the state of delaware on october 24 , 2018. our principal business address is 725 n. hwy a1a , suite c-106 , jupiter , fl 33477. jupiter wellness , inc. is a cutting-edge developer of cannabidiol ( cbd ) based medical therapeutics and wellness products . the company 's clinical pipeline of prescription cbd-enhanced skin care therapeutics address indications including eczema , burns , herpes cold sores , and skin cancer . we are in the early stage of manufacturing , distributing , and marketing a diverse line of consumer products infused with cbd . we have a proprietary , line of products : canisun , caniskin and canidermrx . under the canisun brand , we are marketing patent pending cbd-infused sun care lotion formulas containing various sun protection factors , or spfs . in addition , we are exploring the use of cbd with other prescription and or over-the-counter , or otc , consumer products that have potentially therapeutic and medical applications . specifically , we are exploring the use of such topical solutions for the treatment of eczema , dermatitis ( jw-100 ) , and actinic keratosis ( jw-_100 ) , a non-prescription lotion/lip balm ( jw-200 ) for the treatment of symptoms of cold sores , and a prescription product for the treatment of burns ( jw-101 ) . the canidermrx ( jw-100 ) topical solution for the treatment of eczema dermatitis is the lead product candidate and will be further tested in humans as an investigational cosmetic ingredient followed by clinical trials subject to the regulations of the united states food and drug administration ( “ fda ” ) under an investigational new drug , or ind , application . in february 2021 , we announced the results of our novel cannabidiol-aspartame combination treatment jw-100 clinical trial which has shown it significantly reduces isga score in eczema patients . a double blinded placebo controlled interventional study was conducted . subjects were assigned to apply , at home , one of three treatments : jw-100 ( a cbd and aspartame combination topical formulation ) , a cbd only topical formulation , or a placebo topical formulation . after 14 days , the average reduction in the investigators static global assessment ( isga ) score was calculated for each group . additionally , the proportion of subjects achieving ( isga ) score 0 ( clear ) or 1 ( almost clear ) with at least 2 grade improvement from baseline was recorded for each arm of the study . 50 % of subjects in the jw-100 arm achieved isga clear or almost clear ( 1 or 2 ) with at least a 2-grade improvement from baseline after treatment versus 20 % and 15 % in the cbd-only and placebo arms , respectively . the percentage of subjects achieving clear or almost clear with at least a 2-grade improvement from baseline was found to be statistically significant ( p=0.028 ) . jw-100 , a novel topical formulation containing cbd and aspartame , was shown to significantly reduce isga score in atopic dermatitis patients after two weeks of use . the combination of cbd and aspartame was more effective at reducing isga scores than cbd alone . in parallel , we plan to initiate the development of other products . we originally anticipated developmental studies to be completed in 2020 , however , these studies were delayed due to covid-19 . we are also actively seeking to acquire or license products in the otc skin care market that can be infused with cbd and marketed under our caniskin and canidermrx brand names . there can be no assurances that we will acquire or enter into such partnership or licensing agreements . the endocannabinoid system , which is a body system affected by cbd , plays a pivotal role in maintaining a healthy skin through modulating pain sensation , cell proliferation and inflammation . our strategy for treatment of skin indications is , therefore , to focus on the use of cbd containing topical formulations and to explore potential combinations of cbd and other agents that may augment and act synergistically with cbd . we will explore this strategy by conducting controlled clinical trials to try to ultimately gain fda approval for specific indications . 31 canisun brand we developed a cbd-infused sunscreen with broad-spectrum spf protection . we have completed lab testing for cbd solubility-infusing clear , colorless , odorless , and 99.5 % pure cbd isolated with three different sun care active ingredients , homosalate , octisalate and octocrylene , which have already been approved by the fda . the cbd-infused sun care market is fairly nascent in the united states ; we believe that there are currently no major competitors in the category . we see an opportunity to become the leading manufacturer of cbd-infused sun care products , marketing the canisun brand through an extensive digital and social media awareness campaign . we announced the launch of our canisun sun care line of spf 30 , spf 50 and spf 55 face lotion on june 6 , 2019. we also sell our cbd-infused lip balm and cbd-infused spf 30 sunscreen spray on our website canisun.com . story_separator_special_tag from january through september 2019 , we had multiple sales of common stock at $ 0.25 per share . from september through the end of 2019 , we sold our stock at $ 1.00 per share . issuances and grants throughout 2019 were all based upon the last sales price for sales of our stock for cash to third parties . if and when our shares of common stock are publicly listed , we will use the closing share price on a exchange as a basis for valuing our stock grants . recently issued accounting pronouncements in june 2018 , the fasb issued asu 2018-07 , which simplifies the accounting for nonemployee share-based payment transactions . the amendments specify that topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor 's own operations by issuing share-based payment awards . the company has adopted this standard beginning january 1 , 2019. the adoption of this standard did not have a significant impact on our results of operations , financial condition , cash flows , and financial statement disclosures . in may 2014 , the fasb issued asu no . 2014-09 , “ revenue from contracts with customers ” . the new standard provides a five-step approach to be applied to all contracts with customers and also requires expanded disclosures about revenue recognition . the asu is effective for annual reporting periods beginning after december 15 , 2017 , including interim periods and is to be retrospectively applied . the adoption of this standard did not have a significant impact on our results of operations , financial condition , and cash flows . the adoption of this standard is expected to result in additional financial statement disclosures . in february 2016 , topic 842 , “ leases ” was issued to replace the leases requirements in topic 840 , “ leases ” . the main difference between previous gaap and topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous gaap . a lessee should recognize in the balance sheet a liability to make lease payments ( the lease liability ) and a right-of-use asset representing its right to use the underlying asset for the lease term . for leases with a term of 12 months or less , a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities . if a lessee makes this election , it should recognize lease expense for such leases generally on a straight-line basis over the lease term . the accounting applied by a lessor is largely unchanged from that applied under previous gaap . topic 842 will be effective for annual reporting periods beginning after december 15 , 2018 , including interim periods within those annual periods and is to be retrospectively applied . the company has adopted this standard beginning january 1 , 2019. the adoption of this standard did not have a significant impact on our results of operations , financial condition , cash flows , and financial statement disclosures . management does not believe that any recently issued , but not effective , accounting standards , if currently adopted , would have a material effect on our financial statements . 35 results of operations for the year ended december 31 , 2020 the following table provides selected financial data about us for the year ended december 31 , 2020 and 2019 , respectively . replace_table_token_2_th revenues we generated $ 1,065,665 in revenues for the year ended december 31 , 2020 compared to $ 6,455 revenues for the year ended december 31 , 2019. the large increase is due to the company having only nominal operations during 2019. in 2019 , the company focused its efforts on formulating , testing and manufacturing its sunscreen and skin care products . in 2020 , the company ( i ) began marketing its skin care and sunscreen products line , ( 2 ) acquired magical beasts , llc , which expanded its product offerings , sales and marketing capabilities ( 3 ) added additional product lines to its skin care product line , ( 4 ) added a line of hand sanitizer , for a combined sales total of $ 834,812 and acquired srm entertainment ltd which contributed sales of $ 230,853. operating expenses we had total operating expenses of $ 6,730,300 for the year ended december 31 , 2020 compared to $ 913,893 for the year ended december 31 , 2019. operating expenses for the year ended december 31 , 2020 were in connection with our daily operations as follows : ( i ) marketing expenses of $ 82,367 ; ( ii ) research and development of $ 308,367 ; ( iii ) legal and professional expenses of $ 837,698 , consisting of corporate advisory services , registration statement preparation fees , general corporate governance fees ; ( iv ) rent of $ 61,797 ; ( v ) depreciation and amortization of $ 103,392 ; ( vi ) general and administrative expenses of $ 1,784,456 , consisting of payroll and related taxes , travel , meals and entertainment , office supplies and expense and other normal office and administration expenses ; ( vii ) stock based compensation of $ 2,398,140 ; ( viii ) an impairment to goodwill of $ 308,690 ; ( ix ) an impairment to intangible assets of $ 731,628 and ( x ) net interest expense of $ 113,765. we had total operating expenses of $ 913,893 for the year ended december 31 , 2019. operating expenses were in connection with our daily operations as follows : ( i ) marketing expenses of $ 74,145 consisting of internet awareness costs , website development , trade shows and promotional displays ; ( ii ) research and development of $ 108,957 consisting of product

